Guillain-Barre Syndrome-Pipeline Review, H1 2017

Guillain-Barre Syndrome-Pipeline Review, H1 2017


  • Products Id :- GMDHC9225IDB
  • |
  • Pages: 46
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Guillain-Barre Syndrome-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome-Pipeline Review, H1 2017, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.

Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. Risk Factors include influenza virus, mycoplasma pneumonia, Hodgkin's lymphoma and Epstein-Barr virus.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Guillain-Barre Syndrome-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 4 respectively. Similarly, the Universities portfolio in Phase III and Discovery stages comprises 1 and 1 molecules, respectively.

Guillain-Barre Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Guillain-Barre Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Guillain-Barre Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Guillain-Barre Syndrome (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Guillain-Barre Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Guillain-Barre Syndrome-Overview

Guillain-Barre Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Guillain-Barre Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Guillain-Barre Syndrome-Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Annexon Inc

CuraVac Inc

Hansa Medical AB

Regenesance BV

Vitality Biopharma Inc

Guillain-Barre Syndrome-Drug Profiles

ANX-005-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide for Cholera and Guillain-Barre Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit C6 for Guillain-Barre Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Guillain-Barre Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Guillain-Barre Syndrome-Dormant Projects

Guillain-Barre Syndrome-Product Development Milestones

Featured News & Press Releases

Feb 16, 2017: Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barre syndrome

May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain-Barre Syndrome

May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain-Barre Syndrome

Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial

Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays

Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Guillain-Barre Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Guillain-Barre Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Guillain-Barre Syndrome-Pipeline by Akari Therapeutics Plc, H1 2017

Guillain-Barre Syndrome-Pipeline by Annexon Inc, H1 2017

Guillain-Barre Syndrome-Pipeline by CuraVac Inc, H1 2017

Guillain-Barre Syndrome-Pipeline by Hansa Medical AB, H1 2017

Guillain-Barre Syndrome-Pipeline by Regenesance BV, H1 2017

Guillain-Barre Syndrome-Pipeline by Vitality Biopharma Inc, H1 2017

Guillain-Barre Syndrome-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Akari Therapeutics Plc, Annexon Inc, CuraVac Inc, Hansa Medical AB, Regenesance BV, Vitality Biopharma Inc

select a license

Single User License
USD 2000 INR 129140
Site License
USD 4000 INR 258280
Corporate User License
USD 6000 INR 387420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com